RxDoctor Payments Data

Jessica Malinowski, PA

Dermatology · Park Rapids, MNNPI 1811545437

Payments from drug & device makers

$362in general payments, 2019–2025

Across 8 payments — averaging $45.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kerecis Limited$145
  • Baxter Healthcare$88
  • Organogenesis Inc.$40
  • UCB, Inc.$21
  • Lilly USA, LLC$18
  • Incyte Corporation$18
  • plus $33 from 2 others

What the payments were for

  • Food & beverage$362100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$362 in reported general payments places this provider in the 60th percentile of 273 dermatology providers in Minnesota.

See all dermatology providers in Minnesota

Medicare billing

Part B allowed, 2024
$39,043
Medicare patients
287
Services billed
963

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab11$223,133
Humira PenAdalimumab16$177,104
Dupixent PenDupilumab25$91,408
Fluorouracil77$5,699
MethotrexateMethotrexate Sodium70$1,633
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc41$1,492
Fluocinonide31$1,258
Doxycycline Hyclate26$987
Hydroxychloroquine Sulfate15$973
Clobetasol Propionate24$888
Metronidazole16$739
Clindamycin Phosphate14$599
Betamethasone Valerate12$581
Doxepin Hcl24$480
Triamcinolone Acetonide46$364

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$17$223,13311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 273 dermatology providers in Minnesota.

Other dermatology in Park Rapids

See the full list for Minnesota

Where these figures come from

Is this you, or does something look wrong? →